AbbVie pegs growth to booming Skyrizi, Rinvoq in post-merger future. But neurology could be a ‘sleeper’
With its $ 63 billion merger with Allergan in the rearview, the new AbbVie is facing a major challenge as U.S. biosimilars for Humira cast a pall over the near-term future. But AbbVie figures its homegrown prospects will keep driving growth—and a couple of surprises from Allergan could make the forecast even rosier. After six… Read More »
